1
Home
Companies

Rain Therapeutics

Rain Therapeutics
Leadership team

Mr. Avanish Vellanki M.B.A. (Co-Founder, CEO & Chairman)

Dr. Robert C. Doebele M.D., Ph.D. (Co-Founder, Member of Scientific Advisory Board, Pres & Chief Scientific Officer)

Dr. Richard P. Bryce MBChB, MFPM, MRCGP (Exec. VP & Chief Medical Officer)

Products/ Services
Biotechnology, Health Care, Therapeutics
Number of Employees
0 - 50
Headquarters
Fremont, California, United States
Established
2017
Company Registration
SEC CIK number: 0001724979
Traded as
NASDAQ:RAIN
Social Media
URL
https://www.rainoncology.com
Overview
Location

Summary
History
Mission
Vision
Key Team
Recognition and Award
References
Summary
Rain Oncology Inc., a late-stage precision oncology company, engages in developing therapies that target oncogenic drivers to genetically select patients. The company's lead product candidate is milademetan, a small molecule oral inhibitor of MDM2-p53 complex that reactivates p53. It is also developing a preclinical program focused on inducing synthetic lethality in cancer cells by inhibiting RAD52. The company was formerly known as Rain Therapeutics Inc. and changed its name to Rain Oncology Inc. in December 2022. Rain Oncology Inc. was incorporated in 2017 and is headquartered in Newark, California.
History

Founded in 2015, Rain Therapeutics is a clinical-stage company that is discovering, developing and commercializing personalized medicines for cancer patients. The company was formed based on the vision of its founding scientists who identified an opportunity to use precision medicines to treat a broader range of cancer patients than could be addressed with existing therapies.

Mission
Our mission is to provide personalized medicine as a standard of care to cancer patients by discovering and developing new therapies that are tailored to the specific genetic and molecular drivers of their disease.
Vision
Our vision is to advance the standard of care for cancer patients by discovering and developing personalized medicines that can effectively treat the molecular diversity of cancers while optimizing the patient experience.
Key Team

Mr. Nelson D. Cabatuan (Sr. VP of Fin. & Admin.)

Ms. Theresa O'Connell M.S. (Director of Corp. Devel. & Operations)

Dr. Mehdi Paborji Ph.D. (Sr. VP of Technical Operations)

Ms. Vijaya Tirunagaru Ph.D. (Sr. VP & Head of Research)

Mr. Lucio Tozzi (Sr. VP of Clinical Operations)

Ms. Buenaflor Nicolas M.P.H. (VP, Head Global Drug Safety & Pharmacovigilance)

Dr. Nora Ku M.D. (MD & VP of Clinical Devel.)

Recognition and Awards
Rain Therapeutics has been honored with numerous awards and recognition, including “Best Biopharmaceutical Company of the Year” in 2019 by the California Life Sciences Association and “Top Biotechnology Company of the Year” in 2020 by BioWorld.
References

https://in.investing.com/equities/rain-therapeutics

https://finance.yahoo.com/quote/RAIN/profile?p=RAIN

https://www.crunchbase.com/organization/rain-therapeutics

https://www.rainoncology.com

Dive deeper into fresh insights across Business, Industry Leaders and Influencers, Organizations, Education, and Investors for a comprehensive view.

Rain Therapeutics
Leadership team

Mr. Avanish Vellanki M.B.A. (Co-Founder, CEO & Chairman)

Dr. Robert C. Doebele M.D., Ph.D. (Co-Founder, Member of Scientific Advisory Board, Pres & Chief Scientific Officer)

Dr. Richard P. Bryce MBChB, MFPM, MRCGP (Exec. VP & Chief Medical Officer)

Products/ Services
Biotechnology, Health Care, Therapeutics
Number of Employees
0 - 50
Headquarters
Fremont, California, United States
Established
2017
Company Registration
SEC CIK number: 0001724979
Traded as
NASDAQ:RAIN
Social Media
URL
https://www.rainoncology.com